Linnaeus Therapeutics
Linnaeus Therapeutics is a privately held, clinical-stage biopharmaceutical company developing LNS8801, a first-in-class oral GPER agonist, for oncology, cardiometabolic disease, and healthy aging indications.
- Company typePrivate
- Founded2016
- HeadquartersHaddonfield, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Linnaeus Therapeutics does
Linnaeus Therapeutics is a privately held, clinical-stage biopharmaceutical company founded in 2016 by Christopher Natale, PhD, and Todd Ridky, MD, PhD, at the University of Pennsylvania to translate discoveries on G protein-coupled estrogen receptor (GPER) activation into medicines. The company is developing LNS8801, a potent, orally available, first-in-class GPER agonist with a broad dynamic range, structured around three development pillars: oncology (initially metastatic cutaneous and uveal melanoma, including combinations with anti-PD-1/L1 therapy), cardiometabolic disease, and healthy aging. Linnaeus holds composition of matter patents in the United States and Europe extending IP protection into the 2040s and has secured FDA Fast Track designation plus Orphan Drug Designations for both metastatic cutaneous and uveal melanoma.
The business is funded primarily through non-dilutive government sources rather than product revenue. Linnaeus has raised approximately $26.5 million in cumulative funding, including a $12 million Series B led by Kairos Ventures in 2019, four competitive SBIR awards from the National Cancer Institute totaling $8.3 million, and up to $22 million from ARPA-H under the PROSPR program in 2026. Strategic partners include Merck (clinical collaboration combining LNS8801 with KEYTRUDA) and academic collaborators at the University of Pennsylvania, Columbia University, and Tulane University, with the Board of Directors including representatives from Kairos Ventures and Takeda Pharmaceuticals.
Linnaeus is pre-revenue with no commercial products on market; its go-to-market will rely on standard pharmaceutical supply chains upon regulatory approval, supported by clinical trial operations at academic medical centers. With 1-10 employees, the company outsources much of its execution to contract research organizations and academic partners, communicating progress primarily through scientific publications, presentations at major oncology conferences (ASCO, ESMO, AACR), and press releases.
Linnaeus Therapeutics firmographics
Firmographics- Name
- Linnaeus Therapeutics
- Legal name
- Linnaeus Therapeutics, Inc.
- Website
- https://linnaeustx.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Linnaeus Therapeutics is a privately held, clinical-stage biopharmaceutical company developing LNS8801, a first-in-class oral GPER agonist, for oncology, cardiometabolic disease, and healthy aging indications.
- Ownership category
- akta.pro rank
Linnaeus Therapeutics industry classification
Industry- Product category
- Clinical-stage oncology and cardiometabolic biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
- akta.pro secondary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Linnaeus Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Haddonfield
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Linnaeus Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others, Marketing or Sales
Distribution channels1 record
Marketing channels4 records
Linnaeus Therapeutics product offering
Product offeringCore offering
Linnaeus Therapeutics develops LNS8801, a first-in-class, orally available small-molecule agonist of the G protein-coupled estrogen receptor (GPER), being advanced through clinical trials for metastatic cutaneous and uveal melanoma, other advanced solid tumors, cardiometabolic disease, and healthy aging. The company leverages a proprietary GPER agonist platform protected by composition-of-matter patents extending into the 2040s, with FDA Fast Track and Orphan Drug designations supporting an expedited development pathway.
Product overview
Linnaeus Therapeutics is a biopharma company building a platform based on evolutionarily conserved protective biology. The company's single core product is LNS8801, a GPER agonist drug designed for resilience against cancer, cardiometabolic disease, and aging. The development strategy is structured around three pillars: oncology, cardiometabolic disease, and healthy aging. The drug offers convenient oral dosing with exceptional safety and tolerability profile, and has demonstrated clinical antitumor activity alongside cardiometabolic benefits. The company is advancing LNS8801 through clinical trials in oncology while building pipeline expansion into cardiometabolic disease and aging biology.
Differentiator
Problem solved
Functional benefit
Products and services
- LNS8801 First-in-class, orally available small-molecule agonist of the G protein-coupled estrogen receptor (GPER) being developed for metastatic cutaneous and uveal melanoma, other advanced solid tumors, cardiometabolic disease, and healthy aging. Demonstrated oral bioavailability, exceptional safety and tolerability in over 100 patients, clinical antitumor activity, and preliminary cardiometabolic benefits including improvements in LDL cholesterol, blood pressure, weight, and HbA1c. Holds FDA Fast Track designation and Orphan Drug designations for metastatic cutaneous and uveal melanoma.
Companies that use Linnaeus Therapeutics
Customer profileSegments3 records
Ideal customer profiles3 records
Linnaeus Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Linnaeus Therapeutics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and secondary.
- National Institute on Aging (NIA)coreLNS8801 selected for evaluation in the NIA Interventions Testing Program (ITP), one of the most rigorous longevity research initiatives. The ITP evaluates interventions at three independent research centers using genetically diverse mice, providing robust validation for longevity treatments.
- Columbia UniversitysecondaryOngoing research collaboration with Columbia University collaborators publishing preclinical data on GPER activation in uveal melanoma, acute myeloid leukemia, and other cancer models.
- Tulane UniversitysecondaryCollaborative research published on GPER cardioprotection studies showing LNS8801 improved cardiac function, lowered blood pressure, and reduced proteinuria in preclinical models of cardiovascular disease.
- Merck (MSD)coreClinical collaboration agreement to evaluate LNS8801 in combination with KEYTRUDA (pembrolizumab) in patients with advanced cancer. The collaboration was expanded in June 2021 to include multiple additional phase 2 cohorts testing LNS8801 plus KEYTRUDA across selected advanced solid tumors. This represents a significant strategic partnership for clinical development of the GPER agonist in combination with anti-PD-1 therapy.
- University of PennsylvaniacoreFounding institution where company was established in 2016 by Christopher Natale, PhD and Todd Ridky, MD, PhD based on discoveries in GPER activation. Ongoing collaborative research relationship including scientific cofounders publishing preclinical data.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Linnaeus Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Eli Lilly: Global pharmaceutical company with major franchises in women's health, oncology, and cardiometabolic disease. Comparable to Linnaeus as a broad incumbent operating across all three of Linnaeus' target pillars (oncology, cardiometabolic, healthy aging).
- Takeda Pharmaceutical: Global pharmaceutical company with strong oncology, rare-disease, and women's health portfolios. Comparable because Takeda's CSO sits on Linnaeus' board, indicating strategic interest and positioning Takeda as a potential partner/acquirer for the GPER platform.
- Merck & Co. (MSD): Global pharmaceutical company and maker of KEYTRUDA — Linnaeus' existing clinical collaboration partner. Comparable because Merck is the most relevant strategic partner for the LNS8801 combination program and a benchmark for IO-combination deal economics.
- Pfizer: Global pharmaceutical company with extensive oncology, cardiometabolic, and rare-disease pipelines. Comparable to Linnaeus because Pfizer operates as a potential large-pharma partner/acquirer across all three of Linnaeus' therapeutic pillars.
Direct peers
- Radius Health: Specialty biopharmaceutical company focused on women's health, including osteoporosis and novel endocrine therapies. Comparable to Linnaeus given both companies pursue women's-health and hormone-receptor biology with small-molecule approaches.
- TherapeuticsMD: Women's-health-focused pharmaceutical company developing estrogen- and hormone-replacement therapies. Comparable to Linnaeus because both target estrogen-signaling biology in women's health indications, though TherapeuticsMD focuses on traditional hormone therapy rather than GPER-selective agonism.
- Veru Inc. Clinical-stage biopharma developing therapeutics in oncology and women's health, including breast cancer and urology. Comparable to Linnaeus because of its dual focus on oncology and women's health, overlapping with Linnaeus' oncology and estrogen-receptor biology themes.
- Cardiff Oncology: Clinical-stage oncology company developing therapies for melanoma and other cancers. Comparable to Linnaeus because both are clinical-stage, small-cap oncology companies focused on melanoma indications where LNS8801 has received FDA Fast Track and Orphan Drug Designations.
Emerging players
- UNITY Biotechnology: Clinical-stage biotech developing senolytic therapies to address diseases of aging. Comparable to Linnaeus because both target the biology of aging and age-related diseases, representing parallel approaches to the same emerging healthspan therapeutic category.
- Compugen: Clinical-stage immuno-oncology company using a computational platform to identify novel drug targets and develop cancer therapeutics. Comparable to Linnaeus as a small-cap clinical-stage oncology biotech pursuing differentiated mechanism-based cancer therapy.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Linnaeus Therapeutics social profiles
Digital presenceLinnaeus Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Linnaeus Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Linnaeus Therapeutics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Linnaeus Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Linnaeus Therapeutics
What does Linnaeus Therapeutics do?
Linnaeus Therapeutics develops LNS8801, a first-in-class, orally available small-molecule agonist of the G protein-coupled estrogen receptor (GPER), being advanced through clinical trials for metastatic cutaneous and uveal melanoma, other advanced solid tumors, cardiometabolic disease, and healthy aging. The company leverages a proprietary GPER agonist platform protected by composition-of-matter patents extending into the 2040s, with FDA Fast Track and Orphan Drug designations supporting an expedited development pathway.
Is Linnaeus Therapeutics a public or private company?
Linnaeus Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Linnaeus Therapeutics founded?
Linnaeus Therapeutics was founded in 2016. It employs 1 to 10 people.
Where is Linnaeus Therapeutics based?
Linnaeus Therapeutics is headquartered in Haddonfield, United States, in the North America region.
Who are Linnaeus Therapeutics's main competitors?
Broad incumbents on record are Eli Lilly, Takeda Pharmaceutical, Merck & Co. (MSD) and Pfizer. Direct peers are Radius Health, TherapeuticsMD, Veru Inc. and Cardiff Oncology. Emerging players are UNITY Biotechnology and Compugen.
Does Linnaeus Therapeutics have an API?
No public API is recorded for Linnaeus Therapeutics.
What industry is Linnaeus Therapeutics in?
Linnaeus Therapeutics's product category is Clinical-stage oncology and cardiometabolic biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 541714 and its SIC code is 2834.